The price of success: cost-effectiveness of molecularly targeted agents.
The advent of molecularly targeted agents has brought major breakthroughs in oncology. However, because these drugs are expensive and financial resources are limited, attention to their cost-effectiveness is rapidly increasing. It seems that establishment of cost-effectiveness is complex but is determined for the most part by the cost of drug acquisition and the drug's efficacy. This article examines the cost-effectiveness of molecularly targeted drugs.
Sleijfer
S
S
Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands. s.sleijfer@erasmusmc.nl
Verweij
J
J
D000818:Animals; D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000639:trends; D016503:Drug Delivery Systems / Q000191:economics* / Q000639:trends; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000191:economics*
D004364:Pharmaceutical Preparations